切换至 "中华医学电子期刊资源库"

中华口腔医学研究杂志(电子版) ›› 2009, Vol. 3 ›› Issue (01) : 29 -35. doi: 10.3877/cma.j.issn.1674-1366.2009.01.006

基础研究

CD44v3 及CD44v6 在舌鳞癌组织中的表达及意义
王茜1, 潘朝斌2,(), 王建广2, 杨朝晖2, 赵小朋2, 李海刚3   
  1. 1.510405 广州中医药大学第一附属医院口腔科
    2.中山大学附属第二医院口腔颌面头颈外科
    3.中山大学附属第二医院病理科
  • 收稿日期:2008-07-28 出版日期:2009-02-01
  • 通信作者: 潘朝斌
  • 基金资助:
    广东省自然科学基金(07001594)广东省社会发展科技计划项目(2008B03031324)

Expression and the clinical significance of CD44v3 and CD44v6 in tongue squamous cell carcinom

Qian WANG1, Chao-bin PAN1,(), Jian-guang WANG1, Chao-hui YANG1, Xiaopeng ZHAO1, Hai-gang LI1   

  1. 1.The First Affiliated Hospital of Guangzhou Chinese Medicine University,Guangzhou 510405, China
  • Received:2008-07-28 Published:2009-02-01
  • Corresponding author: Chao-bin PAN
引用本文:

王茜, 潘朝斌, 王建广, 杨朝晖, 赵小朋, 李海刚. CD44v3 及CD44v6 在舌鳞癌组织中的表达及意义[J/OL]. 中华口腔医学研究杂志(电子版), 2009, 3(01): 29-35.

Qian WANG, Chao-bin PAN, Jian-guang WANG, Chao-hui YANG, Xiaopeng ZHAO, Hai-gang LI. Expression and the clinical significance of CD44v3 and CD44v6 in tongue squamous cell carcinom[J/OL]. Chinese Journal of Stomatological Research(Electronic Edition), 2009, 3(01): 29-35.

目的

探讨CD44v3 及CD44v6 在舌鳞癌组织中的表达及其与临床病理因素的关系。

方法

免疫组织化学方法检测中山大学附属第二医院口腔颌面头颈外科1996 年1 月至2006 年12 月单纯接受手术治疗的71 例舌鳞癌石蜡标本中CD44v3 及CD44v6 的表达,用SPSS 13.0 统计软件分析CD44v3 及CD44v6 的表达与舌鳞癌患者的年龄、性别、临床分期、肿瘤分化程度、淋巴结转移等临床病理因素的关系。

结果

(1)舌鳞癌组织中CD44v3 及CD44v6 阳性百分数均高于癌旁组织中CD44v3 及CD44v6 阳性百分数(P <0.001)。 (2)舌鳞癌组织中CD44v3 及CD44v6 阳性百分数有统计学相关(Spearman 相关系数为0.494,P <0.001)。(3)淋巴结转移与无淋巴结转移组间舌鳞癌CD44v3 及CD44v6 阳性强度差异均有统计学意义(P 值分别为0.023 及0.019)。

结论

舌鳞癌CD44v3 及CD44v6 表达与淋巴结转移有关,检测它们有助于判断患者的预后。

Objective

The aim of this study was to investigate the expression of CD44v3 and CD44v6 in human tongue quamous cell carcinoma (HTSCC) and the relationship between their expressions and the clinical data.

Methods

71 cases paraffin-embedded specimen of the patients who underwent radical surgery barely from Jan.1996 to Dec.2006, in the Department of Oral and Maxillaficial Surgery, the Second Affiliated Hospital, Sun Yat-sen University were collected.The samples were detected for CD44v3 and CD44v6 expression by immunohistochemistry method.The relationship between the expression of CD44v3 and CD44v6 and the clinical data including age, gender, clinical stage, tumor differentiation was analyzed with SPSS 13.0 soft package.

Results

(1)The percentage of CD44v3 positive cells in HTSCC was significantly higher than that in tumor margin (the mean percentage was 54.32% and 19.24%,respectively, P <0.001).The percentage of CD44v6 positive cells in HTSCC was statistically higher than that in tumor margin (the mean percentage was 35% and 19.24%, respectively, P <0.001).(2)There was a positive relationship between the percentage of CD44v3 positive cells in HTSCC and that of CD44v6 positive cells in HTSCC(rs=0.494,P <0.001).(3)The patients with positive lymph node(s) had higher CD44v3 score and higher CD44v6 score in HTSCC than those people with negative lymph node (P=0.023, 0.019, respectively).

Conclusions

There was a statistically relationship between the expression of CD44v3 (or CD44v6) and lymph node (s) metastasis.Detection of CD44v3 or CD44v6 may be helpful to predict the prognosis of HTSCC patients.

图1 舌鳞癌角化珠CD44v6 染色阴性,周边癌细胞染色多为阳性(SP ×200)
图2 舌鳞癌CD44v6 表达中阳性(SP ×200)
图3 舌鳞癌CD44v3 表达强阳性(SP ×200)
表1 舌鳞癌及癌旁组织中CD44v3 及CD44v6 阳性百分数(±s,%)
表2 舌鳞癌及癌旁CD44v3 及CD44v6 阳性百分数的Spearman 秩相关分析
表3 肿瘤CD44v3 不同阳性强度与临床病理参数的关系(n=71)
表4 舌鳞癌CD44v6 不同阳性强度分组与临床病理参数的关系(n=71)
1
Kuo MY, Cheng SJ, Chen HM, et al.Expression of CD44s, CD44v5, CD44v6 and CD44v7-8 in betel quid chewing-associated oral premalignant lessions and squamous cell carcinomas in Taiwan.J Oral Pathol Med,1998,27(3):428-433.
2
Reategui EP, de Mayolo AA, Das PM, et al.Characterization of CD44v3-containing isoforms in head and neck cancer.Cancer Biol Ther,2006,5(9):1163-1168.
3
Bennett KL, Jackson DG, Simon JC, et al.CD44 isoforms containing exon v3 are responsible for the presentation if heparin-binding growth factor.J Cell Biol, 1995,128(4):687-698.
4
Huang SM, Li J, Harari PM.Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade.Mol Cancer Ther, 2002,1(7):507-514
5
Rys´ J, Kruczak A, Lackowska B, et al.The role of CD44v3 expression in female breast carcinomas.Pol J Pathol, 2003, 54(4):243-247
6
Hefler LA, Concin N, Mincham D, et al.The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a multicenter study.Cancer, 2002,94(1):125-130.
7
Schlessinger J, Lax L, Lemmon, M.Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?Cell, 1995,83(3):357-360.
8
Van der Voort R, Taher TE, Wielenga VJ, et al.Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosion kinase c-Met.J Biol Chem, 1999,274(10):6499-6506.
9
Wang SJ, Wreesmann VB, Bourguignon LY.Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer.Head Neck, 2007,29(6):550-558.
10
刘健,浦剑虹,葛自力.CD44v6 和MMP-9 在口腔鳞癌组织中的表达及其相关性研究.临床口腔医学杂志, 2005,21(6):333-335.
11
肖峥嵘,汪说之,陈新明.CD44v6 在口腔鳞状细胞癌中的表达.口腔颌面外科杂志, 2001,11(3):208-211.
12
田臻,郭伟,张伟国.CD44v6 在不同生物学行为的口腔癌中的表达.上海口腔医学, 2002,11(4):353-355.
13
Stockler M, Wilchen NR, Ghersi D, et al.Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer.Cancer Treat Rev, 2000,26(3):151-168.
14
Yu Q, Stamenkovic I.Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.Gengs Dev, 1999,13(1):35-48.
15
Orian-Rousseau V, Morrison H, Matzke A, et al.Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.Mol Biol Cell, 2007,18(1):76-83.
16
Skotheim RI, Nees M.Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol, 2007,39(7-8):1432-1449.
[1] 王振宁, 杨康, 王得晨, 邹敏, 归明彬, 王雅楠, 徐明. 腹腔镜直肠癌根治术后预置造口与襻式回肠造口短期疗效评价:一项倾向性评分匹配队列研究[J/OL]. 中华普通外科学文献(电子版), 2025, 19(01): 21-27.
[2] 陈宝鹤, 张文卓, 王隽. 头尾侧联合入路腹腔镜右半结肠癌根治术的近中期临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 153-156.
[3] 韦洋, 赵远权, 王小波, 黄海, 陈洁. BCLC 0/A期肝细胞癌患者术后辅助治疗后早期复发风险分析及预测模型建立[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 157-161.
[4] 李峥, 马晋峰. 基于炎症反应评分系统构建预测根治性术后食管胃结合部腺癌患者预后的列线图模型[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 170-175.
[5] 董家旭, 宋美姿, 毕讯. 射频消融术联合TSH抑制治疗甲状腺微小乳头状癌的效果及生存预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 200-203.
[6] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[7] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[8] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[9] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[10] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[11] 汪玥, 陆衡, 曹洁, 陆博文. GNG4蛋白在胃肠道间质瘤中的表达及预后意义[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(01): 6-10.
[12] 赵鸿鹰, 江荣科, 王宇, 朱梅, 李艳芳. CEACAM19调控PI3K/AKT信号通路对胃癌发病及预后判断的研究[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(01): 16-22.
[13] 张海玲, 陈丹丹, 朱季军, 王晓燕, 张诗琪. 多层螺旋CT联合血清miR-17检测预测胃癌淋巴结转移风险的效果[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(01): 23-28.
[14] 段红良, 赵红梅, 李涛, 辛建锋. 结直肠癌组织SPOCD1表达与临床病理特征及术后复发转移的关系[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(01): 40-45.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要